GWAS Replication Study Confirms the Association of PDE3A–SLCO1C1 with anti-TNF Therapy Response in Rheumatoid Arthritis
2013; Future Medicine; Volume: 14; Issue: 7 Linguagem: Inglês
10.2217/pgs.13.60
ISSN1744-8042
AutoresI. Acosta-Colman, Núria Palau, Jesús Tornero, Antonio Fernández‐Nebro, Francisco J. Blanco, Isidoro González‐Álvaro, Juan D. Cañete, Joan Maymó, Javier Ballina, Benjamín Fernández‐Gutiérrez, À. Olivé, Héctor Corominas, Alba Erra, Oriol Canela‐Xandri, Arnald Alonso, María López‐Lasanta, Raül Tortosa, Antonio Julià, Sara Marsal,
Tópico(s)Tuberculosis Research and Epidemiology
ResumoAim: The present study was undertaken to replicate the association of candidate genes for anti-TNF response in rheumatoid arthritis. Candidate genes were selected from a recent genome-wide association study on anti-TNF response performed in a population from Denmark. Materials & methods: Genomic DNA was obtained from 315 Spanish rheumatoid arthritis patients having received an anti-TNF agent as their first biological therapy. SNPs from NR2FR2, MAP2K6, CBLN2 and PDE3A–SLCO1C1 candidate loci were genotyped. Results: The PDE3A–SLCO1C1 locus rs3794271 SNP showed a highly significant association with anti-TNF treatment response (p = 1.74 × 10-5). Combining the statistical evidence from the Spanish and Danish rheumatoid arthritis cohorts, the associated rs3794271 SNP reached a genome-wide significance level of association (p = 3.3 × 10-10). Conclusion: The present findings establish the PDE3A–SLCO1C1 locus as a strong genetic marker of anti-TNF therapy response. Original submitted 9 January 2013; Revision submitted 13 March 2013
Referência(s)